Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Oral Drug Delivery Systems: Delayed-Release Systems01:11

Oral Drug Delivery Systems: Delayed-Release Systems

Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...
Oral Drug Delivery Systems: Continuous-Release Systems01:26

Oral Drug Delivery Systems: Continuous-Release Systems

Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
Dosage Regimen: Fixed Dose01:01

Dosage Regimen: Fixed Dose

Fixed-dose regimens are a common approach to administer drugs to achieve and maintain desired levels of the drug in the body. In this dosing strategy, a specific amount of medication is given at regular intervals, often multiple times a day, to ensure a consistent drug concentration in the bloodstream.
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
Dosage Regimen: Multiple Oral Dosage01:25

Dosage Regimen: Multiple Oral Dosage

Understanding how a drug's concentration fluctuates within the body over time is crucial in pharmacokinetics, particularly with multiple oral doses. A graphical representation of multiple oral dosages provides insight into these dynamics. Typical accumulation curves of a drug's concentration in the body reveal a sawtooth pattern, indicating periodic peaks and troughs correlating with each dose administration and the drug's subsequent elimination.The plasma concentration at any time during an...
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions01:24

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention01:05

Bioavailability Enhancement: Drug Stability Enhancement and GI Retention

Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clostridium difficile arising in a patient with hidradenitis suppurativa on clindamycin and rifampin.

Dermatology online journal·2018
Same author

Squamous cell carcinoma of the cervix arising in a patient on adalimumab � a need for cervical screenings in patients on tumor necrosis factor inhibitors.

Dermatology online journal·2018
Same author

Amoxicillin-induced generalized eruption associated with Epstein-Barr virus reactivation in pregnancy.

International journal of dermatology·2017
Same author

Why rifampin (rifampicin) is a key component in the antibiotic treatment of hidradenitis suppurativa: a review of rifampin's effects on bacteria, bacterial biofilms, and the human immune system.

Dermatology online journal·2016
Same author

Reduction in pain scores and improvement in depressive symptoms in patients with hidradenitis suppurativa treated with adalimumab in a phase 2, randomized, placebo-controlled trial.

Dermatology online journal·2016
Same author

Apremilast (Otezla).

Skinmed·2016
Same journal

Pellagra associated with iron deficiency.

Dermatology online journal·2026
Same journal

Demodicosis: A frequently underrecognized cause of recalcitrant ear pruritus.

Dermatology online journal·2026
Same journal

Association of alopecia areata with COVID-19 vaccination: A vaccine adverse events reporting system analysis.

Dermatology online journal·2026
Same journal

Gender based price differences in 5% minoxidil foam: The impact of generic alternatives and bulk packaging.

Dermatology online journal·2026
Same journal

Retrospective analysis of filler complications reported in the manufacturer and user facility device experience database from 2015 to 2025.

Dermatology online journal·2026
Same journal

Characterizing barriers to care in patients with hidradenitis suppurativa.

Dermatology online journal·2026
See all related articles

Related Experiment Video

Updated: Jun 27, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
08:38

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

Myfortic (mycophenolate sodium) delayed-release tablets.

Ansa Qureshi1, Noah Scheinfeld

  • 1Department of Dermatology, Columbia University, New York, NY, USA. NSS32@columbia.edu

Dermatology Online Journal
|December 9, 2008
PubMed
Summary
This summary is machine-generated.

Myfortic, a novel enteric-coated mycophenolate sodium formulation, offers a potential solution for reducing gastrointestinal side effects associated with mycophenolic acid (MPA) therapy.

Related Experiment Videos

Last Updated: Jun 27, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
08:38

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

Area of Science:

  • Immunopharmacology
  • Gastroenterology
  • Drug Delivery Systems

Background:

  • Mycophenolic acid (MPA) is an immunosuppressant widely used in organ transplantation.
  • Gastrointestinal (GI) side effects are common with MPA therapy, impacting patient adherence and outcomes.
  • Enteric coating is a drug delivery strategy to mitigate GI irritation.

Purpose of the Study:

  • To introduce Myfortic, a new enteric-coated mycophenolate sodium (EC-MPS) formulation.
  • To evaluate the potential of EC-MPS to reduce gastrointestinal side effects compared to conventional MPA formulations.

Main Methods:

  • Formulation development of enteric-coated mycophenolate sodium (EC-MPS).
  • Preclinical and/or clinical studies assessing GI tolerability and MPA pharmacokinetics.
  • Comparative analysis of GI adverse events between EC-MPS and standard MPA.

Main Results:

  • The enteric coating protects MPA from premature release in the stomach.
  • EC-MPS demonstrated a favorable gastrointestinal tolerability profile in preliminary assessments.
  • Pharmacokinetic data suggests comparable systemic absorption of MPA from EC-MPS.

Conclusions:

  • Myfortic (EC-MPS) represents an advancement in MPA drug delivery.
  • This formulation holds promise for improving the gastrointestinal safety of immunosuppressive therapy.
  • Further clinical trials are warranted to confirm the benefits of Myfortic in transplant recipients.